2025-12-19 - Analysis Report
Okay, here's a comprehensive analysis of Teladoc Health Inc. (TDOC) based on the provided data:

**1) Return Rate Comparison:**

*   **Ticker:** TDOC
*   **Company Overview:** Teladoc Health Inc. is a virtual healthcare company offering telehealth services.
*   **TDOC Cumulative Return:** -64.70%
*   **S&P 500 (VOO) Cumulative Return:** 100.13%
*   **Divergence:** -164.2 (Relative Divergence: 0.5)

**Analysis:**

TDOC has significantly underperformed the S&P 500.  The divergence of -164.2 indicates a substantial difference in cumulative returns. The relative divergence of 0.5 suggests that this divergence is currently near the lower end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR      | MDD  | Alpha    | Beta   | Cap(B) |
|------------|-----------|------|----------|--------|--------|
| 2015-2017  | 77.0%     | 70.4% | 51.0%    | -0.1   | 6.2    |
| 2016-2018  | 101.0%    | 69.4% | 86.0%    | -0.1   | 8.8    |
| 2017-2019  | 141.0%    | 73.8% | 118.0%   | 0.3    | 14.9   |
| 2018-2020  | 105.0%    | 80.9% | 81.0%    | 0.3    | 35.5   |
| 2019-2021  | -78.0%    | 80.9% | -125.0%  | 0.3    | 16.3   |
| 2020-2022  | -252.0%   | 85.9% | -251.0%  | -0.9   | 4.2    |
| 2021-2023  | -315.0%   | 85.9% | -316.0%  | -1.8   | 3.8    |
| 2022-2024  | -93.0%    | 85.9% | -113.0%  | -1.9   | 1.6    |
| 2023-2025  | -36.0%    | 81.6% | -99.0%   | -0.8   | 1.3    |

**Analysis:**

*   **CAGR:**  The Compounded Annual Growth Rate shows explosive growth in earlier periods, followed by significant decline in recent years.
*   **MDD:** Maximum Drawdown has been consistently high, indicating substantial risk and volatility.
*   **Alpha:** The negative Alpha figures in recent years indicate that TDOC has significantly underperformed its benchmark, considering the risk-free rate.
*   **Beta:** The Beta values, particularly the negative ones in later periods, suggest an inverse correlation with the market. While the beta was positive from 2017-2021, the negative beta from 2020-2025 suggests that the stock is likely moving in opposite direction of the market.
*   **Cap(B):** The market capitalization shows significant contraction since 2018-2020.

**2) Recent Stock Price Fluctuations:**

*   **Current Price:** $7.14
*   **Previous Close:** $7.25
*   **Price Change:** -1.52%
*   **5-day SMA:** $7.338
*   **20-day SMA:** $7.42
*   **60-day SMA:** $7.9174

**Analysis:**

TDOC's price is currently below all three moving averages (5-day, 20-day, and 60-day SMA), indicating a downtrend.  The recent price drop and negative change from the previous close further confirm this downward momentum.

**3) Technical Indicators & Expected Return:**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 33.21 (Approaching oversold territory)
*   **PPO:** -0.11 (Bearish)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash
*   **Recent Relative Divergence Change:** 0.0 (Short-term decline)
*   **Expected Return:** -10274.4% (Extremely negative)

**Analysis:**

*   The MRI suggests a medium investment risk, but this should be viewed with caution given the other negative indicators.
*   The RSI of 33.21 is nearing the oversold level (typically below 30), which *could* indicate a potential for a short-term bounce, but doesn't guarantee it.
*   The negative PPO confirms the bearish trend.
*   The *extremely* negative expected return suggests a very pessimistic outlook for long-term investment in TDOC, relative to the S&P 500.
*   The small negative divergence change suggests the short term price is declining.

**4) Recent News & Significant Events:**

*   **[2025-11-25]** "Teladoc Health (TDOC): Assessing Valuation After Recent Short-Term Share Price Rebound": This suggests a recent small recovery is being re-evaluated.
*   **[2025-12-18]** "Teladoc Health, Inc. (NYSE:TDOC) Receives Consensus Rating of "Hold" from Brokerages": Indicates a neutral sentiment from analysts overall.
*   **[2025-12-18]** "Responsive Playbooks and the TDOC Inflection": This suggests the company is strategizing to manage changes.
*   **[2025-12-17]** "Teladoc Health (TDOC): Reassessing Valuation After New $13.6 Million ESOP Shelf Registration Filing":  An ESOP (Employee Stock Ownership Plan) can be a positive or negative signal depending on the details. The "reassessing valuation" aspect is important to note.
*   **[2025-12-03] & [2025-12-04]**  "Teladoc Health president Bliss sells $34,310 in stock" & "Insider Sale: President of BetterHelp of $TDOC Sells 4,209 Shares": Insider selling is generally considered a negative signal.

**Analysis:** The news headlines paint a mixed picture. Analyst are neutral, but there are reassessments of valuation and the sale of stock by insiders.

**4-2) Analyst Opinions:**

*   **Consensus:** Hold
*   **Mean Rating:** 2.67 (Hold)
*   **Number of Opinions:** 22
*   **Target Price:** $9.18 (Average) / $12.00 (High) / $7.00 (Low)

**Analysis:** The analyst consensus is "Hold," with a mean rating of 2.67, indicating a neutral stance. The average target price of $9.18 suggests a potential upside from the current price, but the low target of $7.00 indicates that some analysts see further downside risk.

**5) Recent Earnings Analysis:**

| Date       | EPS   | Revenue       |
|------------|-------|---------------|
| 2025-10-30 | -0.28 | 0.63 B$       |
| 2025-07-30 | -0.19 | 0.63 B$       |
| 2025-05-01 | -0.53 | 0.63 B$       |
| 2024-10-31 | -0.19 | 0.64 B$       |
| 2025-10-30 | -0.19 | 0.64 B$       |

**Analysis:**

The company is consistently reporting negative EPS (Earnings Per Share), indicating a lack of profitability. Revenue has been relatively stable around $0.63-0.64 billion, but it hasn't translated into positive earnings.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|----------|---------------|
| 2025-09-30 | $0.63B   | 70.12%       |
| 2025-06-30 | $0.63B   | 69.85%       |
| 2025-03-31 | $0.63B   | 68.73%       |
| 2024-12-31 | $0.64B   | 70.50%       |
| 2024-09-30 | $0.64B   | 71.94%       |

**Capital and Profitability:**

| Quarter    | Equity  | ROE      |
|------------|---------|----------|
| 2025-09-30 | $1.39B  | -3.56%   |
| 2025-06-30 | $1.42B  | -2.30%   |
| 2025-03-31 | $1.43B  | -6.52%   |
| 2024-12-31 | $1.49B  | -3.25%   |
| 2024-09-30 | $1.51B  | -2.21%   |

**Analysis:**

*   Revenue has been relatively consistent, but profit margins fluctuate. Even with those margins, the company is not generating positive earnings as shown above.
*   Equity is decreasing, and ROE (Return on Equity) is consistently negative, confirming that the company is not generating returns for its shareholders.

**7) Comprehensive Analysis:**

Teladoc Health (TDOC) presents a challenging investment picture.

*   **Underperformance:** It has significantly underperformed the S&P 500 and exhibits a substantial negative divergence.
*   **Downtrend:** The stock is in a downtrend, trading below key moving averages.
*   **Negative Indicators:**  Technical indicators like PPO and the negative expected return point to continued weakness.
*   **Profitability Concerns:** The company is consistently reporting negative EPS and ROE, highlighting fundamental profitability issues. The profit margin is not translating to positive earnings.
*   **Mixed Signals:** While analyst consensus is "Hold," recent news includes valuation reassessments and insider selling, which are concerning.
*   **Risk:** While the MRI suggests medium risk, the high MDD, negative Alpha and Beta in recent years suggest otherwise.

**Conclusion:** Based on the provided data, investing in TDOC at this time carries significant risk. The negative expected return, continued losses, and negative technical indicators warrant caution. Investors should carefully consider the company's ability to turn around its profitability and demonstrate sustained growth before considering an investment.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.